Frank Rimerman Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Frank Rimerman Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$257K	Sell	5,763 -44	-0.8%	-$2.5K	0.01%	545
2026 Q2	$460K	Buy	5,807 +26	+0.4%	+$1.96K	0.03%	428
2026 Q1	$434K	Hold	5,781	–	–	0.03%	410
2025 Q4	$457K	Buy	5,781 +16	+0.3%	+$1.2K	0.03%	402
2025 Q3	$377K	Buy	5,765 +2	+0%	+$98	0.02%	424
2025 Q2	$228K	Buy	+5,763	New	+$189K	0.02%	517

Other funds holding IONS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Tweedy, Browne Co Stamford, Connecticut $1.23B AUM 16.54% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Frank Rimerman Advisors's IONS Position: Q3 2026 in Review

Frank Rimerman Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 0.76% in Q3 2026, selling an estimated $2.5K and leaving 5,763 shares worth $257K. The position accounts for 0.01% of the portfolio, ranked #545.

Frank Rimerman Advisors first reported a position in IONS in Q2 2025 and has held it in 6 quarters since. The position peaked at $460K in Q2 2026. 194 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

Frank Rimerman Advisors held 5,763 shares of Ionis Pharmaceuticals worth $257K as of Q3 2026.
Frank Rimerman Advisors sold 44 Ionis Pharmaceuticals shares in Q3 2026, an estimated $2.5K.
Ionis Pharmaceuticals made up 0.01% of Frank Rimerman Advisors's portfolio in Q3 2026, its #545 holding.
Frank Rimerman Advisors first reported a position in Ionis Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Frank Rimerman Advisors's Ionis Pharmaceuticals position peaked at $460K in Q2 2026.
194 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.